|Series A, 2/10 |
Vesalius Biocapital Partners
Société Régionale d'Investissement de Wallonie
Life Sciences Partners
|Series B, 3/12 |
Boehringer Ingelheim Venture Fund
Mitsui Global Investment
PrometheraÂ® Biosciences is a biopharmaceutical company, spin-off of the UniversitÃ© Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.
PrometheraÂ® Biosciences’ mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers.
PrometheraÂ® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):